

ACCEPTED MANUSCRIPT

Title:

**Nearly Half of Metastatic Brain Disease Patients Prescribed Ten Fractions of Whole Brain Radiation Therapy Die Without Completing Treatment**

Authors:

Shearwood McClelland III MD, Namita Agrawal MD, Kevin Shiue MD, Gregory K Bartlett CMD, Richard C Zellars MD, Gordon A Watson MD PhD, Susannah G Ellsworth MD

Institution:

Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN

Keywords: Whole Brain Radiation Therapy, Metastatic Brain Disease, Unfinished Treatment, 30-Day Survival, Fractionation, Palliative Care

Conflict of Interests: No authors have any conflicts of interest.

Source of Financial Support/Funding Statement: This manuscript received no funding

Corresponding Author:

Shearwood McClelland III, MD

Department of Radiation Medicine, Indiana University School of Medicine

535 Barnhill Drive, RT 041

Indianapolis, IN 46202

Phone: 317-944-1315

Fax: 317-944-2486

Email: [drwood@post.harvard.edu](mailto:drwood@post.harvard.edu)

---

This is the author's manuscript of the article published in final edited form as:

McClelland, S., Agrawal, N., Shiue, K., Bartlett, G. K., Zellars, R. C., Watson, G. A., & Ellsworth, S. G. (2019). Nearly Half of Metastatic Brain Disease Patients Prescribed 10 Fractions of Whole-Brain Radiation Therapy Die Without Completing Treatment. *Journal of Pain and Symptom Management*. <https://doi.org/10.1016/j.jpainsymman.2019.04.022>

**To the Editor**

Since 1954, whole brain radiation therapy (WBRT) has been an integral palliative treatment modality for brain metastases<sup>1</sup>. For over 40 years, the standard palliative WBRT regimen in the United States has been 30 Gy in 10 fractions over two weeks, although shorter regimens have been reported<sup>2-4</sup>. While prolonged ( $\geq 10$  fractions) WBRT regimens have historically been favored due to a perceived improvement in neurocognitive side effect profile, hypofractionated WBRT is equally effective for disease control<sup>2,3</sup> and reduces the burden of prolonged treatment on patients and caregivers near the end of life. Additionally, some patients cannot finish planned WBRT due to declining performance status (PS); however, the likelihood of failing to complete standard-fractionation WBRT has not been rigorously evaluated. To address this void, the following analysis was performed to allow for improved objective quantifying of this commonly utilized palliative modality.

**Methods**

An IRB-approved prospective institutional database identified 52 patients receiving WBRT (30 Gy/10 fractions) for brain metastases between April 2015-December 2018. Functional independence was defined as Karnofsky PS (KPS)  $\geq 70$ ; 30-day mortality was defined as death within 30 days immediately after final radiation treatment. Statistical analyses were performed in SPSS v.24 (IBM Corp., Armonk, NY).  $P < 0.05$  was considered statistically significant.

**Results**

Of 52 patients who began WBRT, 29 (55.8%) completed prescribed therapy; demographics are depicted in Table 1. Patients completing WBRT were significantly more likely to be functionally independent at

baseline and had lower 30-day mortality. Mean treatment duration for patients completing WBRT was 15.3 days. Of the 23 patients failing to complete standard WBRT, 30-day mortality was nearly 70%.

## Discussion

Brain metastases carry a poor prognosis; median survival following WBRT is 3-4 months<sup>2,3,5</sup>. However, this relatively long anticipated survival following WBRT has historically provided practitioners with confidence that prolonged treatment regimens will not adversely affect QOL. Our results indicate this widespread presumption may be incorrect. The large minority (nearly 50%) of patients prescribed standard ten-fraction WBRT who died without completing treatment suggests that a large subset of this patient population may not live as long as generally presumed. Consequently, adjustments to clinical practice of both prescribing and requesting WBRT should be considered, particularly since the data originally establishing ten-fraction WBRT as the standard of care demonstrated no significant difference in survival or local control between 30 Gy in ten fractions, 20 Gy in five fractions, or 10 Gy in one fraction<sup>2-3</sup>. Additionally, Level I evidence has demonstrated no neurocognitive advantage of prolonged WBRT<sup>6</sup>. For the significant proportion of WBRT patients with <4 weeks to live, any reduction in treatment time represents a meaningful reduction in the rigors of daily traveling for a treatment that confers no survival advantage over shorter schedules.

Furthermore, the modern WBRT patient population is likely enriched for poor-KPS patients and those with a larger disease burden, as more favorable patients (i.e., those with oligometastatic disease) are increasingly likely to receive stereotactic radiosurgery instead. Median survival following WBRT in the modern era may therefore actually be shorter compared with historical data collected before stereotactic radiosurgery was considered standard of care for good KPS patients with 1-3 brain metastases.

Limitations of this study include its small sample size, retrospective nature, and single-institution source of data, each of which independently limit the scope of our conclusions. However, the relative standardization of WBRT practice increases the applicability of our findings.

### **Conclusions**

Over 40% of patients prescribed standard ten-fraction WBRT regimens are unable to tolerate the full duration of treatment. With nearly half of patients dying within 30 days of standard 10-fraction WBRT, hypofractionated (i.e., 1- or 5-fraction) regimens may reduce the physical and financial burden of treatment on this population and should be strongly considered by clinicians, especially in poor-performance status patients.

**References**

1. Chao JH, Phillips R, Nickson JJ. Roentgen-ray therapy of cerebral metastases. *Cancer*. 1954;7:682-689.
2. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys*. 1980;6:1-9.
3. Borgelt B, Gelber R, Larson M, et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys*. 1981;7:1633-1638
4. Langley RE, Stephens RJ, Nankivell M, et al. Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer? *Clin Oncol (R Coll Radiol)*. 2013;25:e23-30.
5. Nieder C, Norum J, Hintz M, Grosu AL. Short survival time after palliative whole brain radiotherapy: can we predict potential overtreatment by use of a nomogram? *J Cancer*. 2017;8:1525-1529.
6. Murray KJ, Scott C, Greenberg HM, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. *Int J Radiat Oncol Biol Phys*. 1997;39:571-574.

Table 1: Clinical characteristics of patients who did vs. did not complete WBRT.

Patient Demographic	Failed WBRT Completion (n = 23)	Completed WBRT (n = 29)	P value
Age (mean)	58.0	58.2	0.966
Male	11 (47.8%)	11 (37.9%)	0.576
Female	12 (52.2%)	18 (62.1%)	
Inpatient	14 (60.1%)	12 (41.4%)	0.264
Outpatient	9 (29.9%)	17 (58.6%)	
<i>KPS</i> $\geq$ 70	4 (17.4%)	13 (44.8%)	0.043
<i>Death within 30 days of final fraction</i>	16 (69.6%)	9 (31.0%)	0.011

## Author Contributions:

Study concept and design: McClelland

Acquisition, analysis, or interpretation of data: McClelland, Agrawal, Shiue, Bartlett, Watson, Ellsworth

Drafting of the manuscript: McClelland

Critical revision of the manuscript for important intellectual content: McClelland, Agrawal, Shiue, Bartlett, Zellars, Watson, Ellsworth

Statistical analysis: McClelland, Ellsworth

Administrative, technical, or material support: McClelland, Agrawal, Shiue, Watson, Ellsworth

Study supervision: Ellsworth, Watson, Zellars